Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other financing activities (2018 - 2023)

Spyre Therapeutics (SYRE) has disclosed Other financing activities for 7 consecutive years, with $1.8 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Other financing activities fell 12.0% year-over-year to $1.8 million, compared with a TTM value of $6.5 million through Jun 2023, down 22.14%, and an annual FY2024 reading of $1000.0, up 106.25% over the prior year.
  • Other financing activities was $1.8 million for Q2 2023 at Spyre Therapeutics, up from $1.7 million in the prior quarter.
  • Across five years, Other financing activities topped out at $2.1 million in Q3 2021 and bottomed at $1.1 million in Q1 2019.
  • Average Other financing activities over 5 years is $1.7 million, with a median of $1.7 million recorded in 2020.
  • The sharpest move saw Other financing activities soared 36.15% in 2020, then plummeted 31.85% in 2022.
  • Year by year, Other financing activities stood at $1.2 million in 2019, then surged by 36.15% to $1.6 million in 2020, then rose by 29.9% to $2.1 million in 2021, then tumbled by 31.85% to $1.4 million in 2022, then increased by 24.39% to $1.8 million in 2023.
  • Business Quant data shows Other financing activities for SYRE at $1.8 million in Q2 2023, $1.7 million in Q1 2023, and $1.4 million in Q4 2022.